FCG Advisors’s Bristol-Myers Squibb BMY Stock Holding History

FCG Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$56.4M	Buy	936,133 +8,379	+0.9%	+$504K	13.27%	1
2020 Q2	$54.6M	Sell	927,754 -2,583	-0.3%	-$154K	14.23%	1
2020 Q1	$51.9M	Buy	930,337 +685,317	+280%	+$41.9M	14.79%	1
2019 Q4	$15.7M	Buy	245,020 +238,941	+3,931%	+$13.7M	4.51%	5
2019 Q3	$308K	Buy	6,079 +228	+4%	+$10.7K	0.09%	111
2019 Q2	$265K	Buy	5,851 +3	+0.1%	+$140	0.08%	122
2019 Q1	$279K	Sell	5,848 -207	-3%	-$10.3K	0.09%	117
2018 Q4	$315K	Buy	6,055 +411	+7%	+$22.1K	0.12%	95
2018 Q3	$350K	Sell	5,644 -183	-3%	-$10.9K	0.12%	94
2018 Q2	$322K	Buy	5,827 +2	+0%	+$108	0.12%	94
2018 Q1	$368K	Buy	5,825 +1	+0%	+$64	0.13%	88
2017 Q4	$357K	Sell	5,824 -298	-5%	-$18.6K	0.13%	82
2017 Q3	$390K	Buy	6,122 +184	+3%	+$10.7K	0.14%	77
2017 Q2	$331K	Sell	5,938 -188	-3%	-$10.2K	0.11%	103
2017 Q1	$318K	Buy	6,126 +67	+1%	+$3.67K	0.13%	84
2016 Q4	$354K	Sell	6,059 -361	-6%	-$19.7K	0.16%	72
2016 Q3	$346K	Sell	6,420 -10,769	-63%	-$692K	0.11%	80
2016 Q2	$1.26M	Buy	17,189 +11,727	+215%	+$829K	0.4%	44
2016 Q1	$349K	Buy	5,462 +362	+7%	+$22.8K	0.12%	73
2015 Q4	$351K	Buy	5,100 +1	+0%	+$66	0.21%	62
2015 Q3	$302K	Sell	5,099 -298	-6%	-$18.9K	0.25%	63
2015 Q2	$359K	Sell	5,397 -12,127	-69%	-$799K	0.28%	61
2015 Q1	$1.13M	Sell	17,524 -365	-2%	-$22.9K	0.58%	34
2014 Q4	$1.09M	Buy	17,889 +11,932	+200%	+$673K	0.54%	41
2014 Q3	$276K	Sell	5,957 -13,271	-69%	-$663K	0.18%	58
2014 Q2	$933K	Buy	19,228 +11,565	+151%	+$570K	0.71%	34
2014 Q1	$398K	Sell	7,663 -293	-4%	-$15.6K	0.28%	53
2013 Q4	$423K	Buy	7,956 +598	+8%	+$30.5K	0.29%	48
2013 Q3	$340K	Buy	7,358 +1,653	+29%	+$72.6K	0.24%	53
2013 Q2	$255K	Buy	+5,705	New	+$248K	0.21%	56

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

FCG Advisors's BMY Position: Q3 2020 in Review

FCG Advisors increased its Bristol-Myers Squibb (BMY) stake by 0.9% in Q3 2020, buying an estimated $504K and bringing the position to 936,133 shares worth $56.4M. The position accounts for 13.27% of the portfolio, ranked #1.

FCG Advisors first reported a position in BMY in Q2 2013 and has held it in 30 quarters since. 2,214 funds tracked by Wall St. Rank hold BMY as of Q3 2020.

FCG Advisors held 936,133 shares of Bristol-Myers Squibb worth $56.4M as of Q3 2020.
FCG Advisors bought 8,379 Bristol-Myers Squibb shares in Q3 2020, an estimated $504K.
Bristol-Myers Squibb made up 13.27% of FCG Advisors's portfolio in Q3 2020, its #1 holding.
FCG Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 30 quarters since.
2,214 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2020.

Based on FCG Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.